Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants
Public ClinicalTrials.gov record NCT01318694. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of DEB025/Alisporivir in Combination With Peg-IFNα2a and Ribavirin in Hepatitis C Genotype 1 Treatment-naïve Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the safety and efficacy of alisporivir (ALV; DEB025) triple therapy \[i.e., when added to peginterferon alfa-2a (PEG) and ribavirin (RBV)\] to optimize treatment in treatment-naïve participants with hepatitis C virus (HCV) genotype 1 (GT1)
Study identification
- NCT ID
- NCT01318694
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,081 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2011 (Type not available)
- Primary completion
- Aug 2013 (Actual)
- Completion
- Aug 2013 (Actual)
- Last update posted
- Sep 30, 2016
2011 – 2013
United States locations
- U.S. sites
- 32
- U.S. states
- 15
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Beverly Hills | California | 90211 | — |
| Novartis Investigative Site | Oakland | California | 94612 | — |
| Novartis Investigative Site | San Diego | California | 92101 | — |
| Novartis Investigative Site | San Diego | California | 92123 | — |
| Novartis Investigative Site | San Diego | California | 92128 | — |
| Novartis Investigative Site | Ventura | California | 93003 | — |
| Novartis Investigative Site | Bradenton | Florida | 34209 | — |
| Novartis Investigative Site | Maitland | Florida | 32751 | — |
| Novartis Investigative Site | Tampa | Florida | 33607 | — |
| Novartis Investigative Site | Springfield | Illinois | 62703 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46237 | — |
| Novartis Investigative Site | Shreveport | Louisiana | 71130-3932 | — |
| Novartis Investigative Site | Baltimore | Maryland | 21202 | — |
| Novartis Investigative Site | Baltimore | Maryland | 21229 | — |
| Novartis Investigative Site | Minneapolis | Minnesota | 55404 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | St Louis | Missouri | 63128 | — |
| Novartis Investigative Site | Omaha | Nebraska | 68198 | — |
| Novartis Investigative Site | Newark | New Jersey | 07102 | — |
| Novartis Investigative Site | Brooklyn | New York | 11230 | — |
| Novartis Investigative Site | New York | New York | 10016 | — |
| Novartis Investigative Site | New York | New York | 10021 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28203 | — |
| Novartis Investigative Site | Fayetteville | North Carolina | 28304 | — |
| Novartis Investigative Site | Arlington | Texas | 76012 | — |
| Novartis Investigative Site | Dallas | Texas | 75246-2096 | — |
| Novartis Investigative Site | Dallas | Texas | 75390 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | San Antonio | Texas | 78215 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84124 | — |
| Novartis Investigative Site | Fairfax | Virginia | 22031 | — |
| Novartis Investigative Site | Newport News | Virginia | 23602 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 114 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01318694, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 30, 2016 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01318694 live on ClinicalTrials.gov.